PBAC Public Summary Documents – December 2017
Page last updated: 9 November 2018
Public Summary Documents relating to the December 2017 PBAC meeting.
- Adalimumab: Injection 40 mg in 0.4 mL pre-filled syringe and Injection 40 mg in 0.4 mL pre-filled pen; Humira®
- Cabozantinib: Tablet 20 mg, 40 mg and 60 mg; Cabometyx®
- Everolimus: Tablet, dispersible, 2 mg, Tablet, dispersible, 3 mg, Tablet, dispersible, 5 mg; Afinitor® - Updated 26 October 2018
- Fluticasone furoate with umeclidinium and vilanterol: Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose; Trelegy® Ellipta® - Updated 9 November 2018
- Romidepsin: Powder for I.V. infusion 10 mg; Istodax®
- Tenofovir with emtricitabine:
- Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg; Truvada®
- Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg; Tenofovir Disoproxil Emtricitabine Mylan 300/200®
- Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg; Tenofovir EMT GH®
